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INTRODUCTION
Portal hypertension is the consequence of an increase in the splanchnic blood flow 
secondary to vasodilation and increased resistance to the passage of blood through the 
cirrhotic liver1. Development of oesophageal varices is one of the major complications of 
portal hypertension2. Its prevalence varices from 50-60% in patients with cirrhosis of the 
liver3.  After varices have developed, about one-third of patients die of bleeding gastro-
oesophageal varices4. The risk of initial bleeding from varices is 25-35% within two years 
with most first bleeding episodes occurring within one year after detection of varices5. The 
reported mortality from first episode of variceal bleeding ranges from 40-70%.
In 1996, The American Association for the study of liver disease stated that all 
cirrhotic patients should be screened for the presence of oesophageal varices when portal 
hypertension  is  diagnosed.  Recently,  the  Baveno  III  consensus  conference  on  portal 
hypertension recommended that all cirrhotic patients should be screened for the presence 
of  oesophageal  varices  when  liver  cirrhosis  is  diagnosed6.  Repeat  endoscopy  is 
recommended at 2-3 years intervals in patients without varices and at 1-2 years interval in 
patients with small varices to evaluate the development or progression of varices7.
However,  this  approach  has  two  major  limitations.  Endoscopy  is  an  invasive 
procedure and secondly the cost effectiveness of this approach is also questionable8, as only 
9-36% patients with cirrhosis are found to have varices on screening endoscopy. It may 
therefore be more cost effective to routinely screen patients at high risk for the presence of 
varices, so as to reduce the increasing burden and procedure costs of endoscopy units. 
Certain biochemical, clinical and ultrasonographic parameters alone or together have good 
predictive power for non-invasively assessing the risk of bleeding from varices. However, 
the factors that predict the presence of varices are not as well-defined. Identification of 
non-invasive  predictors  of  oesophageal  varices  will  enable  us  to  carry  out  upper  GI 
endoscopy in selected groups of patients, thus avoiding unnecessary intervention and at the 
same time not missing the patients at risk of bleeding.
1
AIM OF THE STUDY
 To  identify  the  clinical,  biochemical,  haematological  and 
ultrasonographic parameters associated with presence of oesophageal 
varices in patients with cirrhosis of liver without any previous evidence 
of GI bleeding.
 To assess  the  ability  of  these  parameters  as  non  invasive  tools  to 
predict the presence of oesophageal varices.
 To  identify  candidates  for  surveillance  endoscopy  based  on  the 
presence of these parameters.
2
MATERIALS AND METHODS
Study design: Prospective, cross-sectional, randomised analysis study.
The  study  was  carried  out  at  the  Institute  of  Internal  medicine, 
Government General, Hospital, Chennai from January 2004 to January 2006.
Inclusion criteria were as follows
 Patients with cirrhosis of liver without any past history of upper (or) 
lower gastrointestinal bleed were included in the study.
 Diagnosis of cirrhosis was based on a combination of physical findings 
when  present  like  Gynaecomastia,  Ascites,  splenomegaly  (etc), 
impaired liver  function  tests  (ie)  deranged clotting profile  and low 
serum albumin  and  irregular  liver  surface  with  coarse  echoes  (or) 
shrunken liver and ratio of transverse caudate lobe to transverse right 
lobe width >0.659 an ultrasonographic examination.
Exclusion criteria were as follows
 Patients with present or previous history of bleed.
 Patients  on previous/current treatment with Beta blockers,  Diuretics 
(or) anti-platelet drugs.
 Patients who had undergone sclerosis (or) band ligation of oesophageal 
varices, TIPSS (or) surgery for portal hypertension.
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 Active alcohol abuse (less than six months abstinence)
 Patients with serum albumin <1.5 gm
All  patients  included  in  the  study  were  subjected  to  detailed  history, 
clinical examination and blood investigations. Clinical examination of the study 
population was concentrated on the physical findings in cirrhotic patients, and 
special emphasis was on the presence of a palpable spleen. Other features like 
Jaundice, Gynaecomastia, spider naevi, Hepatic flap and Ascites were also noted.
Routine blood investigations like Blood urea, sugar serum creatinine and 
serum electrolytes were taken along with blood for hepatitis serology and liver 
function tests. Platelet count was estimated using automated analyser (sysmex 
KX-21). Hepatitis B surface antigen and anti-HCV antibody were investigated in 
all blood samples. Liver function tests were done and included  SGOT, SGPT, 
Alkaline phosphatase,  serum  albumin and Serum-Bilirubin.  The prothrombin 
time was also estimated for all the patients. All patients in the study group were 
classified into child's grade A/B/C based on child-pugh criteria10,11.
Chest  X-ray and ECG were taken for  all  patients.  In  addition,  all  the 
patients were subjected to ultrasonographic examination to assess the liver size, 
structure and the size of the portal vein, and size of spleen. A 3.5MHZ transducer 
was used for USG study.
All patients underwent upper GI endoscopy to evaluate for the presence of 
and the degree of oesophageal varices. Oesophageal varices were classified into 
small and large varices based on the following findings.
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• Small oesophageal varices were defined as those that flatten with 
insufflation or minimally protrude into the oesophageal lumen.
• Large  varices  were  defined  as  those  which  protrude  into  the 
oesophageal lumen and touch each other (or) fill at least 50% of the 
oesophageal lumen12.
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REVIEW OF LITERATURE
Cirrhosis  is  a  pathologically  defined  entity  that  is  associated  with  a 
spectrum  of  characteristic  clinical  manifestations.  The  cardinal  pathologic 
features  reflect  irreversible  chronic  injury  of  the  hepatic  parenchyma  and 
extensive fibrosis in association with the formation of regenerative nodules.
CLINICAL FEATURES OF HEPATIC CIRRHOSIS
• Hepatomegaly (although liver may also be small)
• Jaundice
• Ascites
• Circulatory changes
♦ Spider telangiectasia, palmar erythema, cyanosis
• Endocrine changes
♦ Loss of libido, hair loss
♦ Men: gynaecomastia, testicular atrophy, impotence
♦ Women: breast atrophy, irregular menses, amenorrhoea
• Hemorrhagic tendencies
♦ Bruises, purpura, epistaxis, menorrhagia
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• Portal hypertension
♦ Splenomegaly,  collateral  vessels,  variceal  bleeding,  fetor 
hepaticus
• Hepatic (portosystemic) encephalopathy
• Other features
♦ Pigmentation, digital clubbing, low-grade fever
Child-pugh classification of prognosis in cirrhosis
Score 1 2 3
Encephalopathy None Mild Marked
Bilirubin (mol/L) <34 <34-50 >50
Albumin (g/L) >35 28-35 <28
Prothrombin time (seconds prolonged) <4 4-6 >6
Ascites None Mild Marked
Add the indvidual scores: <7=Childs'A
7-9=Childs'B
>9=Childs'C
SURVIVAL IN CIRRHOSIS
Child-pugh 
grade
Survival (%) Hepatic 
deaths (%)1 year 5 years 10 years
A 82 45 25 43
B 62 20 70 72
C 42 20 0 85
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PROGNOSIS
The overall  prognosis  in cirrhosis  is  poor.  Many patients  present  with 
advanced  disease  and/or  serious  complications  that  carry  a  high  mortality. 
Overall, only 25% of patients survive 5 years from diagnosis but, where liver 
function is  good,  50% survive for  5  years  and 25% for  upto 10  years.  The 
prognosis is more favourable where the underlying cause of the cirrhosis can be 
corrected, as in alcohol misuse, haemochromatosis and Wilson's disease.
Laboratory  tests  give  only  a  rough  guide  to  prognosis  in  individual 
patients.  Deteriorating  liver  function,  as  evidenced  by  jaundice,  ascites  or 
encephalopathy,  indicates  a  poor  prognosis  unless  a  treatable  cause  such  as 
infection  is  found.  Increasing  plasma bilirubin,  falling  plasma albumin or  an 
albumin concentration <30 g/L, marked hyponatraemia (<120mmol/L not due to 
diuretic therapy) and a prolonged prothrombin time are all bad prognostic signs. 
The course of cirrhosis is uncertain, as unforeseen complications such as variceal 
bleeding may lead to death unexpectedly.
PORTAL HYPERTENSION
Portal hypertension is one of the prime complications of cirrhosis. Patients 
developing  clinical  features  or  complications  of  cirrhosis  usually  have  portal 
venous pressures above 12 mmHg.
COMPLICATIONS OF PORTAL HYPERTENSION 
1. Variceal bleeding
2. Congestive gastropathy
3. Hypersplenism
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4. Ascites
5. Renal failure
6. Hepatic encephalopathy
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION
Normal Physiology
The  movement  of  portal  blood  across  the  liver  is  dependent  on  the 
pressure gradient between the portal and hepatic veins13. Hepatic venous pressure 
in  part  reflects  the  state  of  central  venous filling  pressure.  Portal  pressure  is 
determined by the product of portal venous inflow and the vascular resistance of 
this flow:
Portal pressure = portal flow x vascular resistance
Normally,  the  difference  between  portal  venous  pressure  and  hepatic 
venous pressure is never greater than 4mm Hg. A compliant liver acts as a blood 
reservoir to maintain a normal hepatic pressure gradient14. When outflow pressure 
increases, an increasing number of sinusoids are recruited to accommodate these 
changes. Thus, elevations of hepatic venous pressures do not result in similar 
increases in portal pressure.
The main site of portal vascular resistance in humans appears to reside at 
the level of the hepatic sinusoids15.
Portal venous inflow is the sum of the flows from the 3 main splanchnic 
tributaries16. The splenic vein joins the inferior mesenteric vein at the level of the 
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pancreatic body and tail, where pancreaticoduodenal vessels also enter. Superior 
mesenteric venous drainage from the small and proximal large intestine joins the 
splenic vein at a site superior to the pancreatic head, forming the portal vein 
trunk.  The  coronary  vein  drains  the  venous  circulation  of  the  lesser  gastric 
curvature into the proximal portal vein. The gastroduodenal vein collects drainage 
from the area of the pancreatic head.
Total  portal  venous  flow  in  a  normal  man  ranges  between  600  and 
1200ml/min, as measured intraoperatively and by Doppler flowmetry.
The volume of portal flow is regulated by the vascular resistance of the 
splanchnic  arteries17.  Changes  in  portal  inflow  result  from  modifications  in 
splanchnic arteriolar resistance, as seen with physiologic events such as a change 
in posture or in the postprandial state. The increase in portal blood flow after a 
meal can be prevented by pre-administration of somatostatin, an inhibitor of the 
release  of  several  gastrointestinal  hormones  that  may  mediate  the  arteriolar 
vasodilatation that occurs after feeding. Portal venous oxygen content decreases 
after a meal because of increased intestinal arteriovenous extraction of oxygen.
Hemodynamics in Portal Hypertension
Vascular Resistance
Theoretically,  a rise in portal  pressure could stem from an increase in 
either portal flow or vascular resistance. Under normal conditions, a rise in portal 
flow can be accommodated by the compliant hepatic sinusoidal bed so that portal 
pressure  increases  only  in  extreme conditions.  For  example,  although splenic 
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flow increases markedly in the presence of massive splenomegaly, the critical 
threshold in the portal flow-pressure relationship is not reached and portal flow-
pressure relationship is  not reached and portal  hypertension does not develop 
unless  increased  vascular  resistance  is  also  present.  This  hemodynamic 
combination  can  be  seen  in  conditions  with  splenomegaly,  such  as  Felty's 
syndrome,  sarcoidosis,  or  lymphomas.  An  exception  is  portal  hypertension 
caused by a high portal flow from an arteriovenous fistula, as with splenic artery 
splenic vein communications, where the flow-volume relation exceeds a critical 
threshold.
The genesis of portal hypertension involves an increase in portal vascular 
resistance  and  is  the  basis  for  its  classification.  Insight  into  the  location  of 
vascular resistance in human cirrhosis has been provided by combined hepatic 
vein and portal  pressure measurements18.  Most  measurements in nonalcoholic 
cirrhosis  show  a  higher  portal  venous  pressure  than  hepatic  venous  wedge 
pressure,  an estimate of  sinusoidal pressure.  This  indicates  the presence of  a 
presinusoidal component,  probably related to inflammatory activity or fibrotic 
changes in the portal triads. In alcoholic cirrhosis, the vascular resistance must 
reside at  the level of the sinusoids because portal  and hepatic venous wedge 
pressures are similar.
The  pathogenesis  of  the  increased  sinusoidal  resistance  in  alcoholic 
cirrhosis is controversial. The concept of a pathogenic role for the architectural 
rearrangement and development of fibrotic septa in cirrhosis has been replaced by 
an emphasis  on sinusoidal events.  Hepatocyte enlargement,  resulting from an 
alcohol-induced  accumulation  of  fat  and  protein,  may  compress  the  liver 
sinusoids and obstruct portal flow.
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Studies  of  precirrhotic  portal  hypertension  in  baboons  chronically  fed 
alcohol have suggested that the degree of perivenular and pericellular fibrosis 
induced by alcohol correlates with in vivo measurements of portal pressure. This 
further implicates the hepatic sinusoids as the site of increased vascular resistance 
in alcoholic cirrhosis. Capillarization of these low-resistance channels, with loss 
of sinusoidal fenestrae, appearance of collagen in the space of Disse, and the 
presence of  contractile myofibroblasts,  may contribute  to the  development of 
increased sinusoidal resistance.
A relation between hepatocyte size and intrahepatic pressure in alcoholic 
liver disease was found for only mild to moderate pressure elevations, although 
the accuracy of intrahepatic pressure measurements has not been confirmed by 
others. In nonalcoholic cirrhosis, a more complex relation exists between these 
parameters.
Portal blood flow and the systemic circulation
Two models have been proposed to explain the alternations of portal flow 
in  response  to  portal  hypertension:  the  "backward"  and  "forward"  flow 
hypotheses. The first is based on a rise in portal venous pressure triggering a 
myogenic response that reduces splanchnic arterial inflow. As a net result, portal 
pressure  values  drift  back  toward  normal.  If  the  splanchnic  circulation  is 
considered  as  2  organs  in  series  (the  gastrointestinal  tree  and the  liver),  the 
backward flow hypothesis predicts that inflow into the gastrointestinal tree would 
be reduced as a result of this rise in portal venous pressure. Even when portal 
hypertension  is  fully  established,  the  backward  component  contributes  to  its 
maintenance.
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The forward flow hypothesis, in which portal venous inflow is increased, 
is  based  on  observations  in  several  experimental  models  and  patients.  This 
paradoxical increase in portal venous inflow contributes to the maintenance of 
portal hypertension. As a hemodynamic syndrome, portal hypertension is unique 
in exhibiting both increased inflow and increased resistance.
The  increase  in  portal  inflow  occurs  as  part  of  a  more  generalised 
hemodynamic disturbance, the `hyperdynamic" circulation. This is characterized 
by peripheral vasodilatation, a reduction in peripheral vascular resistance, and an 
increase in plasma volume. As a result, cardiac output and heart rate increase. 
Decreases  in  splanchnic and muscular  arterial  resistance are the  main factors 
contributing to the decrease in systemic vascular resistance. Variable effects are 
seen on the renal circulation, in which compensatory mechanisms such as renal 
sympathetic  nerve  activity,  renin-angiotensin,  and  circulating  catecholamines 
may induce renal vasoconstriction in spite of a decreased peripheral  vascular 
resistance.
The  hyperdynamic  circulatory  state  is  seen  in  many  forms  of  portal 
hypertension.  Humoral  factors  may  be  responsible  for  the  development  of 
peripheral vasodilatation. Glucagon levels are elevated in the presence of portal 
hypertension and portosystemic shunts. Other postulated humoral factors include 
prostacyclin, prostaglandins, bile salts and endotoxin mediated activation of nitric 
oxide.
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PORTAL HYPERTENSION AS A HEMODYNAMIC SYNDROME
Splanchnic hemodynamics
♦ Increased portal vascular resistance
♦ Increased portal venous inflow
♦ Portosystemic shunting
Systemic hemodynamics
♦ Arterial vasodilatation
♦ Increased plasma volume
♦ Decreased systemic vascular resistance
♦ Increase in cardiac output
♦ Reduction in mean arterial pressure
♦ Rise in heart rate
Regional blood flows
♦ Increased muscle blood flow
♦ Decreased cerebral blood flow
♦ Variable renal blood flow
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A  sequence  of  events  that  leads  to  the  hyperdynamic  state  has  been 
proposed. Although the primary pathophysiologic event is arterial vasodilation, a 
hyperdynamic state would not develop unless sodium was retained by the kidney, 
a process mediated by the activation of compensatory mechanisms triggered by 
the  same  vasodilatation.  Plasma  volume  is  then  expanded,  which  triggers  a 
further decrease in peripheral vascular resistance.
Collateral circulation
When portal pressure reaches a critical value, porto-systemic collaterals 
may develop. In alcoholic cirrhosis, a corrected portal pressure of 10 to 12mm Hg 
appears  to  be necessary  for  the  development  of  oesophageal  varices19.  These 
collaterals represent the opening of embryonic channels or redirection of flow 
within existing veins, rather than the formation of new blood vessels.
Five main pathways of portosystemic collaterals exist
1. Opening of the umbilical vein
2. Reversal  of flow in the coronary vein,  feeding the development of 
oesophageal varices.
3. Short  gastric  veins  arise  from the  splenic  vein  feeding  the  gastric 
varices.
4. Splenorenal collaterals
5. Reversal  of  flow  in  the  inferior  mesenteric  vein,  feeding  the 
development of anorectal varices.
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Alternations in the volume of blood flow may also induce changes in the 
vascular resistance of the collateral bed. A rise in flow increases vessel diameter 
and a reduction of flow results in opposite changes, with a smaller vessel offering 
an  increased  resistance  to  flow.  The  resistance  to  flow  of  a  fluid  in  a 
nondistensible vessel  is  related to the length of the vessel  (1) and the fluid's 
viscosity (n) and is inversely related to the further power of the radius (r), so that 
minor changes in vessel diameter markedly affect resistance to flow (Poiseuille's 
law).
Resistance = 8nlπr4
Most pharmacologic agents used for the treatment of portal hypertension 
reduce portal pressure by reducing portal blood flow. The relation between vessel 
radius and vessel flow that has been delineated indicates that a reduction in flow 
may cause a rise in vascular resistance.  This is  an important principle in the 
pharmacologic treatment of portal hypertension.
Rupture of oesophageal varices
The mechanisms for the rupture of oesophageal varices have not been 
fully elucidated. The "corrosion" hypothesis postulated that reflux of gastric acid 
injured the mucosa of the lower part of the oesophagus with subsequent erosion 
into the submucosal varies. However, measurements of lower sphincter pressure 
and  pH  in  the  lower  oesophagus  failed  to  show  evidence  of  increased 
gastroesophageal reflux in patients with bleeding oesophageal varices. Attention 
has shifted to the "explosion" theory, in which oesophageal wall tension reaches a 
critical level and rupture occurs.
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Wall tension in a system of artificial varices is related to the intraluminal 
pressure and the vessel's  radius and is  inversely related to its  wall  thickness. 
Laplace's  law states that  a vessel's  radius plays a major role in wall  tension, 
providing a physical basis for the clinical observation that large varices20 and 
those at a higher pressure are more prone to bleed. Measurements of oesophageal 
wall thickness, the third element in this equation, cannot be made with current 
technology but may be of importance when they are available. A relation between 
variceal  pressure  and the risk of  hemorrhage has  been studied by  measuring 
variceal pressure by means of an endoscopic capsule21. Patients who bled from 
varices  had  a  considerably  higher  pressure  than  non  bleeding  patients  with 
cirrhosis and oesophageal varices.
High portal pressures can arise from common daily activities. Elevation of 
portal pressure to values greater than 100mm Hg has been observed during the 
Valsalva  maneuver.  Administration  of  an  anticholinergic  can  also  increase 
variceal size. The genesis of variceal rupture may be related to daily events in 
which pressure rises abruptly to extremely high values22.
Influences of Portal Hypertension on Other organs
Hypersplenism may occur in the absence of splenomegaly. Alterations of 
the splenic microcirculation, with fibrotic changes in the splenic sinusoids, favor 
entrapment of red cells, white cells (especially polymorphonuclear leukocytes), 
and  platelets.  However,  the  bone  marrow  remains  active,  and  infection  or 
bleeding seldom results from leukopenia or thrombocytopenia, respectively. In 
the absence of other factors that affect the platelet count (alcohol, medications), 
thrombocytopenia, between 50,000 and 125,000 platelets/nm3 is an indicator of 
portal hypertension in cirrhosis.
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Hypoxemia, with an arterial partial pressure of oxygen between 60 and 
80mm  Hg,  is  a  common  finding  in  established  portal  hypertension. 
Administration of 100% oxygen does not correct the hypoxemia, suggesting that 
functional  pulmonary  arteriovenous  shunting  is  the  basic  defect.  Anatomic 
connections  have  been demonstrated  on  the  pleural  surface  and  termed  lung 
"spiders".  Vasodilatation  of  pulmonary  capillaries,  as  part  of  the  generalised 
process of systemic vasodilatation may increase the distance for oxygen diffusion 
between the blood and alveolus,  resulting in functional  shunt.  The degree of 
hypoxemia can be severe.
Pulmonary  hypertension  develops  in  a  few  patients,  regardless  of  the 
etiology  of  portal  hypertension.  The  pathophysiology  is  unclear.  Histologic 
studies do not suggest microscopic pulmonary embolism as a possibility. Rather, 
vasoactive substances arising from the splanchnic territory, which now by pass 
the  liver,  may  induce  permanent  changes  in  the  pulmonary  vasculature. 
Serotonin, thought to be elevated in these patients, is of particular interest as it has 
been implicated in the pathogenesis of pulmonary hypertension associated with 
the carcinoid syndrome.
CLASSIFICATION OF PORTAL HYPERTENSION
A logical  classification  of  portal  hypertension  is  based  on  the  site  of 
increased resistance to portal flow. Five main groups can be delineated according 
to  presinusoidal,  sinusoidal,  or  postsinusoidal  block.  Presinusoidal  and 
postsinusoidal  portal  hypertension  can  be  further  subdivided  into  intra-or 
extrahepatic  causes.  Although  the  differential  diagnosis  is  extensive,  liver 
cirrhosis is the leading cause of portal hypertension in the West.
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Presinusoidal Prehepatic
Presinusoidal  prehepatic  portal  hypertension is  most  commonly  due to 
portal vein thrombosis. A blood clot in the portal vein can have several causes; 
however, a definitive diagnosis cannot be made for many patients. Many of these 
idiopathic  cases may represent an early manifestation of  a myeloproliferative 
syndrome. When the colony-forming units were quantitated after bone marrow 
culture,  a  diagnostic  criterion for  myeloproliferative syndrome,  many patients 
with  idiopathic  portal  hypertension  met  criteria  for  the  diagnosis  of  this 
hematologic disorder.
Catheterization of the umbilical vein in newborns has been associated with 
the development of omphalitis with secondary portal vein thrombosis. Over the 
years, bridging collaterals develop toward the liver, resulting in a "cavernous" 
appearance of the portal vein. The prognosis is relatively good because these 
patients have normal liver function, variceal hemorrhage is better tolerated, and 
the incidence of bleeding decreases after the second decade.
Disorders  of  the  coagulation  system  may  present  as  portal  vein 
thrombosis. These include congenital deficiencies of natural anticoagulants such 
as deficiency of antithrombin III, protein C, protein S, and plasminogen activator. 
An acquired lupus anticoagulant may also predispose patients to this thrombotic 
event.
Diseases  of  the  adjacent  organs  may  also  cause  portal  vein  thrombi. 
Invasion into the portal vein by carcinoma of the head of the pancreas or common 
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bile duct denotes inoperability; carcinomas of the pancreatic body and tail affect 
the  splenic  vein.  Cirrhosis  has  been  viewed  as  predisposing  to  portal  vein 
thrombosis because of stasis.
Classification of portal hypertension
Presinusoidal portal hypertension
Extrahepatic
Portal vein thrombosis
Intrahepatic
Schistosomiasis (S.mansoni, S.japonica)
Sarcoidosis
Felty's syndrome
Arsenic poisoning
Idiopathic portal hypertension
Congenital hepatic fibrosis
Primary biliary cirrhosis
Sinusoidal portal hypertension
Alcoholic cirrhosis
Vitamin A intoxication
Renal transplantation
Nodular regenerative hyperplasia
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Postsinusoidal portal hypertension
Intrahepatic
Veno-occulsive disease
Senecio alkaloids
Alcoholic hepatitis (venular sclerosis type)
Extrahepatic
Budd-Chiari syndrome
Congenital web
Splenic vein thrombosis may give rise to gastric varices with hemorrhage. 
If  the  liver  is  normal,  the  gastric  varices  drain  toward  the  liver  through the 
coronary vein and esophageal varices may be absent. Chronic pancreatitis and 
many of the previously discerned disorders that cause portal vein thrombosis may 
also give rise to this segmental abnormality.
Presinusoidal intrahepatic
A wide range of disorders are included in this category, but portal venule 
obstruction is the common link. It can occur as a result of vascular obliteration 
(non cirrhotic portal fibrosis) or as a result of inflammatory activity in the portal 
triad (early stage of primary biliary cirrhosis, lymphoma) that impinges on the 
portal venule system.
Schistosomiasis is the most common entity in this group. Eggs shed by the 
parasite into the splanchnic venous tributaries lodge in the portal vein radicles 
within the liver. A granulomatous, fibrotic reaction develops around the eggs of 
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either Schistosoma mansoni or Schistosoma japonicum, obstructing portal venous 
flow. As a result, prominent hepatomegaly can be detected. Splenomegaly and 
portosystemic collaterals arise as a consequences of portal hypertension. With 
progression  of  the  disease,  cirrhotic  changes  may  develop,  resulting  in  an 
additional component of sinusoidal resistance to portal flow.
Noncirrhotic portal fibrosis (idiopathic portal hypertension) is a common 
cause of portal hypertension in Asia. Obliteration of small portal venules is its 
characteristic feature and liver function is preserved. Noncirrhotic portal fibrosis 
can be reproduced in experimental animals by injection of inactivated Escherichia 
coli into the portal vein, this implies that enteric infection is a possible cause. 
Arsenic poisoning may also present with presinusoidal features.
Inflammatory infiltration of the portal triads coexists with splenomegaly in 
another group of disorders. Examples include Felty's syndrome, lymphoma, and 
sarcoidosis. Several chronic hepatic disorders have a presinusoidal component of 
portal  hypertension;  these  include  nonalcoholic  cirrhosis  and  primary  biliary 
cirrhosis. Congenital hepatic fibrosis may appear with portal hypertension as its 
initial manifestation.
Sinusoidal
Sinusoidal  portal  hypertension is  the  characteristic  feature  of  alcoholic 
liver disease. Hepatitis B-related cirrhosis has also been reported to involve a 
sinusoidal resistance site.
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Perisinusoidal fibrosis with portal hypertension can be seen with vitamin 
A intoxication and after renal transplantation. In the latter, azathioprine may be 
involved  in  its  genesis.  Endothelial  damage  can  also  be  caused  by  other 
compounds with thiol groups.
Classified  within  this  group  is  nodular  regenerative  hyperplasia.  The 
nodules in this entity are delineated not by fibrous tissue but by collapsed liver 
parenchymal cells. Mainly reported in patients with rheumatoid arthritis, it has 
been  described  in  a  wide  variety  of  disorders,  including  myeloproliferative 
disorders,  lymphoma,  macroglobulinemia,  and  myeloma.  Occlusion  of  small 
portal venules may be the primary disorder that leads to collapse of the reticulin 
framework  and  the  appearance  of  nodules  not  surrounded  by  fibrous  tissue. 
Partial nodular transformation, with nodularity confined to the area of the hepatic 
hilum, may be a variant of this disorder.
Postsinusoidal
This  can  occur  within  or  outside  the  liver.  Most  of  the  these  entities 
present with ascites as the main manifestation of portal hypertension.
Primary increase in Portal Venous inflow
Apart from the classification described earlier,  increased portal  venous 
inflow is a rare event that occurs with a direct communication of a splanchnic 
artery to the portal venous system. Examples include a traumatic arteriovenous 
fistula arising from the splenic artery and rupture of an aneurysm of the hepatic 
artery  into  the  portal  vein.  Aneurysms  of  the  splenic  artery  are  seen  in  the 
23
presence of splenomegaly and portal hypertension. They arise as a consequence 
of  increased  splenic  flow and  are  small,  can  be  multiple,  and  seldom cause 
complications.
INVESTIGATION OF THE PORTAL HYPERTENSIVE STATE
Physical Examination
A  full  clinical  evaluation  of  patients  with  portal  hypertension  should 
include elucidation of the cause, evaluation of hepatic function, and screening for 
complications.  The  physical  examination  may  provide  special  clues  to  the 
differential diagnosis.
When patients present with variceal bleeding, cirrhosis cannot be assumed 
to be present and presinusoidal causes should be considered. However,  when 
patients with portal hypertension also exhibit ascites, a presinusoidal etiology is 
unlikely unless severe hypoalbuminemia alters the relation between hydrostatic 
and  oncotic  pressure  in  the  intestinal  capillaries.  Cirrhosis  may  eventually 
develop  in  schistosomiasis,  and  ascites  may  result  from  sinusoidal  portal 
hypertension.
Liver size may offer clinical clues. A small liver in the presence of portal 
hypertension is suggestive of cirrhosis.  The consistency of the liver edge can 
provide additional information, because a normal edge argues against a sinusoidal 
etiology.  The  detection  of  a  hepatic  bruit  may  suggest  primary  carcinoma 
presenting with variceal bleeding as its initial manifestation. A venous hum in the 
periumbilical area indicates high flow through a patent umbilical vein, excluding 
portal vein thrombosis as a cause.
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The appearance of a common ailment such as hemorrhoids can seldom be 
interpreted  as  an  initial  sign  of  portal  hypertension.  However,  proctoscopic 
examination may reveal additional signs, such as the presence of rectal varies.
Conventional Radiology
A chest radiography may show an enlarged azygos vein appearing as a 
mass in the right hilar region or enlarged pulmonary arteries when pulmonary 
hypertension is associated with portal hypertension. Fundico antral varices may 
be misinterpreted as mass lesions on upper gastrointestinal radiographs.
Angiography of  mesenteric  vessels  provides  anatomic information  and 
some functional data. Splenoportography offers the best anatomic detail but has 
seldom  been  used  because  of  concern  about  splenic  puncture.  Small-gauge 
needles may be safe when optimal imaging is needed. Venous phases of arterial 
injections can be enhanced with subtraction techniques, giving better anatomic 
detail.
Computed tomography with injection of a contrast agent not only images 
the splanchnic vessels but also provides information about possible liver disease 
as well as the status of the hepatic veins. Thrombosis of splanchnic vessels can 
easily be visualized. Similar concepts extend to real-time ultrasonography with 
Doppler scanning, which can provide accurate determination of the portal flow 
direction. Hepatofugal flow, described in 8% of patients with cirrhosis, can give 
rise to an angiographic "pseudothrombosis" image of the portal vein, because 
contrast  material  injected  into  the  splenic  artery  flows  toward  the  variceal 
collaterals without visualization of the portal vein. Current noninvasive imaging 
techniques rapidly exclude the presence of a thrombus.
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MEASUREMENT OF PORTAL PRESSURE
Direct measurements of portal venous pressure can be obtained by direct 
puncture of portal tributaries or of venules within the liver. Splenic pulp pressure, 
measured at the time of splenoportography, may accurately reflect portal venous 
pressure  but  is  associated  with  risk  of  hemorrhage  from  the  puncture  site. 
Catheterization  of  the  umbilical  vein,  has  been  re-evaluated  with  use  of  the 
Doppler technique. Percutaneous transhepatic measurements of portal pressure 
can  be  obtained  at  the  time  of  portography.  Direct  measurements  in  portal 
tributaries can also be made at the time of surgery.
All these techniques require an additional measurement of hepatic venous 
pressure to evaluate the pressure gradient across the liver. Also, organ puncture 
can occur in patients with liver disease and coagulopathy. The alternative is to 
approach  the  liver  by  way  of  the  hepatic  vein.  During  hepatic  venous 
catheterization, the catheter is maximally advanced and the vein occluded so that 
a sinusoidal pattern can be seen during injection of dye. Value at this point reflect 
hepatic  venous  wedge  pressure  under  normal  conditions.  Withdrawal  of  the 
catheter into the hepatic vein allows estimation of hepatic venous free pressure. 
Use of the balloon catheter allows measurements of free and wedge pressure from 
one position in the hepatic vein.
Accurate  measurements  require  adequate  calibration  of  pressure 
transducers because the range of normal venous pressure values is narrow. An 
accurate tracing can be identified by its normal respiratory variation and stable 
values; digital readout of pressure values is unacceptable. Permanent records of 
such tracings should be incorporated in the patient's chart.
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When the etiology of portal hypertension is unclear, pressure measured by 
hepatic  venous catheterization can provide useful  clinical  information.  A low 
hepatic venous pressure gradient in the presence of oesophageal varices, strongly 
argues for a presinusoidal etiology. This is the hemodynamic pattern in early 
hepatic  schistosomiasis.  A  high  pressure  gradient  confirms  the  presence  of 
parenchymal liver  disease, but diagnosing its etiology requires additional testing. 
Percutaneous transhepatic measurements are useful in the diagnosis of the Budd - 
Chiari syndrome.
Measurements of pressure are important when therapeutic measures are 
planned.  During  surgery  to  relieve portal  hypertension,  evidence  of  adequate 
decompression is provided by intraoperative pressure measurements. The success 
of  transjugular intrahepatic portosystemic shunt (TIPSS), a nonsurgical technique 
in which a metallic stent is placed between the portal and hepatic veins, can be 
measured by the reduction of portal pressure. When considering pharmacologic 
therapy with beta - adrenergic blockers, reduction of the portal venous pressure 
gradient to critical levels decreases the occurrence of gastrointestinal hemorrhage.
MEASUREMENT OF BLOOD FLOW
Portal Venous Flow
Measurement of portal blood flow had been considered inaccessible in the 
nonsurgical setting, but the use of Doppler flowmetry has allowed estimation of 
portal  flow.  With  this  technique,  portal  mean  velocity  is  measured  with  the 
Doppler signal in the middle of the vessel. Flow is obtained by multiplying an 
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estimate of the cross-sectional area of the portal vein (from the ultrasonographic 
image)  by the calculated mean velocity.  The technique can also be used for 
measurement of arterial inflow, which permits estimation of arteriolar resistance. 
Doppler flowmetry has also been used to assess the effects on portal hypertension 
of histologic events, such as feeding, and the responses to pharmacologic agents. 
A  diminished  response  of  portal  vessels  to  respiration  may  signal  a  critical 
reduction in compliance.
Numerous technical problems may interfere with the accuracy of Doppler 
measurements. These include body habitus, the extent of collateralization (Portal 
vein flow may be markedly decreased with high collateral flow), and respiratory 
variations.  Intra  and  interobserver  variability  in  measurements  of  flow  and 
velocity is considerable. Doppler flowmetry is best suited for comparison within 
the same subject rather than between groups. Nonetheless, its noninvasive nature 
is attractive.
Azygos Venous Flow
Under normal conditions, the azygos vein drains blood from the abdomen 
and lower  extremities.  With  markedly  increased  flow in  portal  hypertension, 
oesophageal varices drain into the azygos and homozygous veins, allowing easy 
identification  of  the  flow  during  catheterization.  With  the  continuous 
thermodilution technique, mean azygos flow was 150 ml min in control subjects; 
in patients with cirrhosis and portal hypertension, the mean value was 550 ml / 
min, with wide variation of results. This increase in azygos flow may not solely 
reflect  increased  collateral  blood  flow  because  drainage  from  the  lower 
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extremities also contributes to azygos flow. However, bile acid concentration and 
oxygen tension are higher in the azygos vein of patients with cirrhosis, reflecting 
the contribution of portal venous blood to this flow.
Measurement of azygos blood flow is useful for indirect estimation of 
collateral blood flow. Its use, however, has been restricted to research laboratories 
and has not been extended to standard clinical practice.
MEASUREMENT OF VARICEAL PRESSURE
Measurement of intravariceal pressure by puncture of oesophagal varices 
before  sclerotherapy  has  been  reported.  Although  initial  reports  suggested 
identical  values  for  intravariceal  pressure  and  portal  pressure,  more  accurate 
measurements  indicated  a  lower  value  for  the  former,  because  pressure  is 
dissipated over a larger vascular bed.
When the sclerotherapy needle is introduced into the varix, it can cross the 
varix and its tip lies in the muscle layer. A manometric capsule has been used to 
measure  variceal  pressure  indirectly.  It  is  mounted  on  an  endoscope  and 
positioned  over  a  variceal  column.  The  pressure  that  obliterates  the  varix  is 
equivalent  to  the  intraluminal  pressure  and  is  recorded  with  its  respiratory 
variation.  This  technique  has  been used to  measure  variceal  wall  tension  by 
multiplying the apparent diameter of the varix by the recorded variceal pressure. 
With these parameters, wall tension was considerably higher in patients who had 
bled from varices than in non-bleeders.
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Quantification of Portosystemic Shunts
Measurement  of  the  degree  of  portosystemic  shunting  is  not  easily 
attainable in patients.  A qualitative assessment can be made by instillation of 
thallium locally in the upper rectum, in the presence of portosystemic shunts, 
some of the thallium escapes hepatic uptake and lodges in the heart. By scanning 
the liver and heart, the presence of portosystemic shunts can be demonstrated in 
patients with chronic hepatitis, establishing the diagnosis of cirrhosis and portal 
hypertension.
The bioavailability of drugs given enterally and highly extracted by the 
liver in their first pass has also been used to measure the extent of portosystemic 
shunts.  Nitroglycerin and sorbitol  have been evaluated.  The bioavailability  of 
partially infused bile acid was estimated in the same way. However, the intestine 
also contributes to the first - pass elimination of these drugs. In addition, precision 
is lost when absorption occurs in intestinal areas that do not belong to the area of 
collateralization . An accurate and reproducible method is not available.
ENDOSCOPIC SCREENING FOR OESOPHAGEAL VARICES
Endoscopic grading of varices-paqet
Grade I : Small varices without luminal prolapse
Grade II : Moderate-sized  varices 
showing luminal prolapse with minimal obscuring of 
the gastro-oesophageal junction.
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Grade III : Large varices showing luminal 
prolapse  substantially  obscuring  the  gastro 
oesophageal junction.
Grade IV : Very  large  varices  completely 
obscuring the gastroesophageal junction.
A  major  cause  of  death  in  patients  with  cirrhosis  is  gastrointestinal 
hemorrhage, most often as a result of the portal hypertensive state23. The 1- year 
bleeding  rate  of  unselected  patients  with  cirrhosis,  without  a  history  of 
hemorrhage, ranges from 6% to 76% and depends on endoscopic features as well 
as  the  degree  of  hepatic  decompensation24.  Mortality  for  the  first  variceal 
hemorrhage ranges from 10% to 65%,25,26 the majority of deaths occur within the 
first 6 weeks after the bleeding episode27. After variceal bleeding has occurred, 
life expectancy is dramatically reduced, with a 1 - year survival of 22% to 60%. 
Patients  who  die  within  the  first  2  years  of  their  index hemorrhage  tend  to 
succumb to variceal bleeding and liver failure; those who survive beyond this 
period die of other complications.
The  prevalence  of  oesophageal  varices  on  a  single  endoscopic 
examination in unselected cirrhotic patients ranges widely. Data on the relation of 
the presence of varices and variceal size to the degree of liver injury, as measured 
by the Child- Pugh score, are conflicting. In some cross - sectional studies using 
the Cox regression analysis, a high Childs, score was predictive of large varices28. 
In others, no direct correlation was found. Varices may be present in patients with 
child's A cirrhosis and absent in those classified with Child's C disease. On this 
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basis,  all  patients with a diagnosis of cirrhosis  should be evaluated by upper 
endoscopy. In one study of patients without varices on an initial examination, 
31%  and  70%  had  varices  on  subsequent  examinations  at  1  and  2  years, 
respectively29.
Barium  oesophagograms  are  good  predictors  of  large  varices  with  a 
sensitivity  of  91%.  Radiologic  characteristics  include  scalloping  of  the 
oesophageal borders and rounded expansions of  the mucosal folds.  However, 
varices must be at least 3 mm for visualization and may often be found to be one 
grade larger  by oesophagoscope than by barium swallow examination.  Hiatal 
hernias make the diagnosis more difficult and gastric fundal varices are difficult 
to distinguish from gastric folds. Thus, oesophagoscope has been considered the 
most  reliable  means  of  establishing  the  diagnosis  of  varices.  Fiberoptic 
oesophagoscope,  developed  in  the  1960s,  has  led  to  improved  tolerance  by 
patients and greater diagnostic accuracy.
The  Japanese  Research  Society  for  Portal  Hypertension  has  proposed 
general  rules  for  recording  endoscopic  findings  of  oesophageal  varices.  In  a 
retrospective analysis, these guidelines were used to establish endoscopic criteria 
to assess the risk of the first episode of hemorrhage30. Those criteria proposed as 
predictive of variceal bleeding included a serpiginous form, red color markings, 
and a fundamental blue, color, while esophagitis was not predictive. Prospective 
studies have confirmed the discriminant function of size and red color signs in 
predicting  the  first  variceal  hemorrhage31,32.  Although  grading  systems  for 
estimation of variceal size differ and have not been completely standardized, an 
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endoscopic evaluation should include assessment of diameter percentage lumen 
occupancy, and a straight or serpiginous form.
Large, serpiginous varices bleed commonly than small, straight vessels; 
still, varices of any size may rupture. Most studies show no relation of variceal 
size to intravariceal pressure as determined by needle puncture or the wedged 
hepatic - inferior vena cava pressure gradient. The size of varices may wax and 
wane on serial endoscopic studies. Spontaneous regression in size occurs with 
improvement of the underlying liver injury. If small varices are seen on initial 
examination, yearly evaluation should be performed. Every 2 years evaluation 
may be adequate for those without varices on the initial evaluation.
Red color  markings  include  cherry  red  spots,  red  wale  markings,  and 
hematocystic  spots.  These  represent  dilated  intraepithelial  and  subepithelial 
venous  channels  on  the  surface,  of  and  in  communication  with,  the  deeper 
submucosal variceal veins. Red spots correlate with variceal size and are found 
on 21%, 42%, and 80% of small, medium, and large varices, respectively. The 
presence of red color signs is not related to Child score. High variceal pressures, 
however, may be important in their development and they may be markers for the 
presence of higher portal pressures. Mean intravariceal pressure determined by 
needle  puncture  is  40% higher  in  patients  with  red  color  signs.  The  risk  of 
bleeding is increased 2-fold in the presence of red color signs. The independence 
of red color signs and variceal size, however has been disputed33.
The  importance  of  these  endoscopic  findings  is  highlighted  by  the 
increasing consideration of prophylactic therapy to prevent variceal hemorrhage. 
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If  the  prediction  of  hemorrhage  is  accurate,  prophylactic  therapy  could  be 
reserved for patients who are at risk of bleeding.
VARICEAL BLEEDING
It  is  one  of  the  most  dangerous  complications  of  portal  hypertension. 
Variceal bleeding occurs from oesophageal varices that are usually located within 
3-5 cm of the oesophagogastric junction or from gastric varices. The size of the 
varices, endoscopic variceal features such as red spots and red stripes, high portal 
pressure and liver failure are all general factors that predispose to bleeding. Drugs 
capable of causing mucosal erosion, such as salicylate and other non - steroidal 
anti  -  inflammatory  drugs  (NSAIDs),  can  also  precipitate  bleeding.  Variceal 
bleeding is often severe, and recurrent bleeding occurs if preventive treatment is 
not given. Bleeding from varices at other sites is comparatively uncommon but 
most often occurs from varices in the rectum or intestinal stomas.
Management of acute variceal bleeding
The priority in acute bleeding from oesophageal varices is to restore the 
circulation with blood and plasma, not least because shock reduces liver blood 
flow and causes  further  deterioration of  liver  function.  Even in patients  with 
known varices, the source of bleeding should always be confirmed by endoscopy 
because about, 20% of such patients are found to be bleeding from some other 
lesion, especially acute gastric erosions.
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TREATMENT TO STOP OESOPHAGEAL VARICEAL BLEEDING AND 
TO PREVENT RECURRENT BLEEDING
Local measures
 Sclerotherapy
 Banding
 Balloon tamponade
 Oesophageal transection
Reduction of portal venous pressure
 Somatostatin
 Vasopressin
 Terlipressin
Prevention of recurrent bleeding
 Sclerotherapy/Banding
 Transjugular intrahepatic portosystemic shunt (TIPSS) 
 Portosystemic shunt surgery
 Propranolol
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Primary prophylaxis of initial variceal bleeding
In  view  of  the  mortality  and  morbidity  associated  with  variceal 
hemorrhage, portosystemic shunts, sclerotherapy and propranolol have all been 
used to try to prevent initial bleeding from varices. Propranolol in a dose of 80 - 
160 mg daily can be used for primary prevention.
ASCITES
Ascites refers to the accumulation of free fluid in the peritoneal cavity and 
is a complication of portal hypertension.
ASCITIC FLUID ANALYSIS
Abdominal paracentesis with ascitic fluid analysis is the most rapid and 
cost-effective  method  of  determining  the  cause  of  ascites.  Under  aseptic 
precautions,  a  standard  1.5  inches  needle  (22  gauge)  is  inserted  below  the 
percussed air-fluid interface and about (50-100ml) fluid is aspirated for analysis. 
The fluid is analysed for protein, content, sugar, cell count, cytology, gram's stain 
and culture.
SERUM ASCITES-ALBUMIN GRADIENT (SAAG)
Ascitic fluid protein concentration is almost entirely dependent on serum 
protein  concentration  (direct  relationship)  and  portal  pressure  (inverse 
relationship).
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The SAAG categorizes ascites better than the total protein concentration. 
The SAAG correlates with portal pressure. It is physiologically based on oncotic-
hydrostatic balance. Portal hypertension results in an abnormally high hydrostatic 
pressure gradient between the portal bed and ascitic fluid. Albumin exerts more 
oncotic force per unit weight than other proteins. The difference between serum 
and ascitic fluid albumin concentration correlates directly with portal pressure34. 
The  SAAG  is  superior  to  the  exudate-transudate  concept  in  the  differential 
diagnosis of ascites35.
Calculating  the  SAAG  involves  measuring  the  serum  albumin 
concentration and ascitic fluid albumin concentration and subtracting the ascitic 
fluid from the serum value. The serum values should always be greater. SAAG is 
not a ratio. If the SAAG is > 1.1 g/dL, the person has portal hypertension with 
more than  95% accuracy. Conversely if the SAAG < 1.1 g/dL, the patient does 
not have portal hypertension with more than 95% accuracy. This test is accurate 
despite ascitic fluid infection, diuresis, therapeutic paracentesis, albumin infusion 
and etiology of liver disease.
Accuracy of the albumin assay at low albumin concentrations such as 0-
1g/dL is important and if not errors occur in calculating SAAG. Another potential 
problem with the SAAG occurs when the serum and ascitic fluid specimens are 
not obtained simultaneously.
Another source of inaccuracy occurs  when a cirrhotic patient has a serum 
albumin level <1.1g/dL. The gradient in falsely low in this setting.
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COAGULATION ABNORMALITIES IN CIRRHOSIS
A variety of hemostatic disorders have been described in cirrhotic patients. 
In  general,  these can be categorized into abnormalities  of  platelet  number or 
function, increased fibrinolysis, or deficient synthesis of clotting factors.
Cirrhosis  is  associated  with  both  quantitative  and  qualitative  platelet 
abnormalities.  Approximately  40%  of  cirrhotic  patients  have  abnormal 
prolongation of the bleeding time to values of more than 10 minutes and platelet 
counts less than 100,00036/mm3. The severity of the thrombocytopenia increases 
with the Child - Pugh classification. This decrease in the number of circulating 
platelets  is  related  in  part  to  platelet  pooling  in  the  spleen  caused by portal 
hypertension and splenomegaly, in part to immunologic destruction of platelets37, 
and  based  on  recent  studies,  in  part  to  diminished  hepatic  production  of 
thrombopoietin38.
Several studies have confirmed the presence of platelet - associated IgG in 
cirrhosis, and immunoglobulin levels increase in proportion to the severity of the 
liver disease39.  This is a particular concern in hepatitis C, in which platelet - 
associated IgG is increased and thrombocytopenia is observed in 41% of patients 
(as compared with 19% of hepatitis B patients). Hepatitis C may also have direct 
effects  because  viral  RNA  can  be  detected  in  circulating  platelets.  Finally 
diminished platelet production may play a role in addition to increased platelet 
sequestration or destruction. Specifically, circulating levels of thrombopoietin, a 
peptide  hormone  produced  primarily  in  the  liver  that  stimulates  platelet 
production, are decreased in some patients with cirrhosis and thrombocytopenia.
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Cirrhosis is also associated with functional abnormalities when circulating 
platelet  are  not  activated  in  a  normal  manner,  resulting  in  defective  clot 
formation40. The decrease in platelet aggregation, as measured by the restitution 
test,  may  be  related  to  decreases  in  glycoprotein  Ib  levels  in  the  platelet 
membrane41 or to defective signal transduction within the platelet. Patients with 
bleeding times longer than 7 minutes or a clinical history of bleeding have the 
lowest glycoprotein Ib levels.
Diagnosis
Low platelet counts are commonly associated with physical manifestations 
of portal hypertension, including ascites and splenomegaly. In general, platelet 
counts above 70,000/ mm are well tolerated and do not cause prolongation of the 
bleeding time unless there are associated qualitative platelet abnormalities. Other 
causes of thrombocytopenia, including diminished production, interferon or other 
medications, or decreased thrombopoietin), must be excluded by history and bone 
marrow  examination  when  necessary.  Splenic  sequestration  is  most  often  a 
diagnosis of exclusion, but increased platelet trapping can be visualized directly 
using indium tropolone - 111 labeled platelet when uncertainty exists. Platelet 
associated  IgG  levels  (antiplatelet  antibodies)  should  be  measured  in  most 
patients, especially those with hepatitis C and autoimmune hepatitis, to assess the 
possible contribution of immune - mediated platelet destruction. Prolongation of 
the bleeding can also reflect impaired platelet function. When necessary formal 
studies of platelet aggregation induced by restitution or other measurements can 
be performed.
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Management
In  thrombocytopenia  related  to  portal  hypertension  and  splenic 
sequestration,  there  has  been  limited  clinical  experience  with  splenic 
embolization, aiming to achieve a 40% to 60% reduction in splenic blood flow. 
Although there is some short - term morbidity with this procedure, it can prolong 
platelet  survival  time and decrease  the  spleen  /  liver  uptake  ratio  of  platelet 
uptake.  In  addition,  splenic  embolization  decreases  platelet  -  associated  IgG 
levels,  suggesting that the  improvement  in  platelet  counts is  due not only to 
effects on splenic pooling but also to immunologic mechanisms.
Transjugular  intrahepatic  portosystemic  shunts  represent  an  attractive 
approach  to  treatment  of  splenic  platelet  sequestration  by  lowering  portal 
pressures. However, clinical series are limited in number and do not yet allow 
definitive  conclusions.  In  a retrospective analysis  of  21 patients,  there  was a 
significant  rise  in  platelet  counts  after  shunt  placement  in  patients  with  a 
postshunt portal pressure gradient less than 12 mm Hg. However,  in a larger 
prospective series, this procedure has no beneficial effect on thrombocytopenia. 
Thus,  transjugular  intrahepatic  portosystemic shunt  cannot  be advocated  as  a 
treatment for thrombocytopenia.
In view of association between platelet count,  spleen size,  presence of 
ascites, child pugh's score etc in patients with cirrhosis with portal hypertension, 
we tried to  correlate the  non invasive parameters with endoscopic  finding in 
portal hypertension in an effort to non invasively predict chances of bleed from 
varices in patients with cirrhosis of the liver.
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STATISTICAL ANALYSIS
Statistical  analysis  was  performed  using  SPSS  1.0.0.1.  Results  were 
expressed as mean  ± S.D. Qualitative data were tabulated in frequencies and 
percentages.   Quantitative  data  were  given  in  mean  and  standard  deviation. 
Association between qualitative  data  like  sex,  childs  grade,  Ascites,  palpable 
spleen, hepatic encephalopathy and grade of varices were analysed using pearson 
chi-squared test. Association between qualitative data like Jaundice, Prothrombin 
time, platelet count, serum albumin, SAAG ratio, spleen size, portal vein diameter 
and grade of varices were analysed using oneway analysis of variance, (ANOVA) 
F-test and student t-test. All tests were 2 tailed and a `P' value of <0.05 was 
considered  to  be  significant.  `P  value  <0.001  was  considered  to  be  highly 
significant.
Threshold  of  different  variables  for  the  best  compromise  sensitivity-
specificity was determined using the ROC curve. Then, Multivariate analysis of 
variables  with  significant  correlation  was  carried  out  using  stepwise  logistic 
regression analysis.
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OBSERVATIONS
The total number of patients in the current study were 72. There were 53 
males and 19 females. The Male: Female ratio was 1:0.3. Males formed 73.6% 
and females 26.4% of the study respectively.
SEX AND VARICES GRADE
Sex
Varices grade Total
No varices Small Large
Male 10 (18.9%) 26(49.1%) 17 (32%) 53 (73.6%)
Female 2 (10.5%) 8 (42.1%) 9 (47.4%) 19 (26.4%)
Pearson chi square = 1.63  P = 0.44 (NS)
Of the 53 males, 26 patients (49.1%) had small varices, 17 (32%) had 
large varices while only 10 (18.9%) had no varices as endoscopy. Among the 19 
females in the study 9 of them (47.4%) had large varices while small varices were 
seen  in  8  (42.1%)  and  no  varices  at  all  in  only  2  (10.5%).   No  statistical 
significance was noted between sex and the presence and grade of varices. 
AGE AND VARICES GRADE
Age (Yrs)
Varices grade Total
No varices Small Large
31-40 0 3 (8.8%) 2 (7.7%) 5 (6.9%)
41-50 7 (58.3%) 18 (52.9%) 7 (26.9%) 32 (44.4%)
51-60 3 (33.3%) 12 (35.3%) 10 (38.5%) 26 (36.1%)
>60 1 (8.3%) 1 (2.9%) 7 (26.9%) 9 (12.5%)
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The majority of patients (80.5%) were in the age group 41-60 years. The 
mean age of the patients was 51.07 ± 7.57 years, ranging from 32-65 years. 
Small varices were seen in 18 patients (52.9%) in the age group of 41-50  years 
and majority of large varices were seen in the 51-60 years age group (38.5%).
MEAN AGE GROUP OF PATIENTS
Varices 
grade
No. of 
patients Mean
Std. 
Deviation
ANOVA
F-test
No varices 12 50.83 5.078
F=2.05
P=0.14
Small 34 49.41 5.281
Large 26 53.35 10.276
Total 72 51.07 7.574
P = 0.14 (NS)
The mean age of the patients was highest (53.35 years) for patients with 
large varices and least (49.41 years) for patients with small varices. `P' value 
was not significant to suggest correlation between age and varices.
CHILD'S GRADING AND VARICES GRADE
Child's Grade
Varices grade Total
No varices Small Large
A 8 (66.7%) 12 (35.3%) 2 (7.7%) 22 (30.6%)
B 4 (33.3%) 18 (52.9%) 8 (30.8%) 30 (41.7%)
C 0 4 (11.8%) 16 (61.5%) 20 (27.8%)
Pearson's chi-square = 28.94 P = 0.001 (significant)
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Among the 72 patients studied, 30 patients were in Group B, 22 patients 
in Group A and 20 patients in Group C. 16 out of 20 patients in Group C had 
large grade varices (61.5%), while only 4 (11.8%) had small varices. It was 
noteworthy that all patients in Group C of Childs grading had varices. Small 
varices were observed in 52.8% (ie) 18 patients in Group B. No varices were 
seen in 8 (66.7%) of the Group A patients. A statistically significant association 
was seen between Childs grade C and large grade varices.
ASCITES AND VARICES GRADE
 
ASCITES
Varices grade
TotalNo varices Small Large
Marked 0 1 (2.9%) 8 (30.8%) 9 (12.5%)
Mild 0 15 (44.1%) 16 (61.5%) 31 (43.1%)
nil 12 (100%) 18 (52.9%) 2 (7.7%) 32 (44.4%)
Pearson's chi-square = 34.95 P = 0.001 (significant)
40 out of 72 patients in the study had Ascites. Mild ascites was noted in 
61.5% of  patients  with large  varices,  and marked ascites  was seen only  in 
30.8% of patients with large varices. 92.3% of patients with Ascites had varices 
on endoscopy which was significant.
SAAG RATIO AND VARICES GRADE
Varices 
grade N Mean
Std. 
Deviation t-test
Small 16 (40%) 1.327 0.2205 t=1.19
P=2.42Large 25 (60%) 2.132 2.6918
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SAAG ratio calculated for all patients with Ascites showed a mean of 
1.33 for small varices and 1.59 for large varices respectively. Student's t-test 
revealed a  significant  correlation between a  high SAAG ratio  and grade of 
varices.
PALPABLE SPLEEN AND VARICES GRADE
Palpable 
spleen
Varices grade
TotalNo varices Small Large
Absent 12 (19.%) 34 (53%) 18 (28%) 64 (89.9%)
Present 0 0 8 (100%) 8 (11.1%)
Pearson chisquare = 15.92 P = 0.001 (Significant)
8 out of 72 patients in the study had a palpable spleen, and significantly 
all  of  them had  large  varices  on  endoscopy.  Among the  patients  in  whom 
spleen  was  not  palpable  (89.9%)  only  28%  had  large  varices.  Univariate 
analysis showed a significant 'p' value for a palpable spleen.
ENCEPHALOPATHY AND VARICES GRADE
Encephalopathy
Varices grade
Totalno varices Small Large
Marked 0 1 (2.9%) 3 (11.5%) 4 (5.6%)
Mild 0 5 (14.7%) 13 (50%) 18 (25%)
Nil 12 (100%) 28 (82.4%) 10 (38.5%) 50 (69.4%)
Pearsons  chisquare = 19.72   P=0.001   significant
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Hepatic encephalopathy was noted in 22 out of 72 patients. Out of 26 
patients with large varices 16 patients had encephalopathy (61.5%) and 38.5% 
of  patients  with  large  varices  did  not  have  any  features  of  hepatic 
encephalopathy. Small varices were strongly associated with absence of hepatic 
encephalopathy (82.4%). All patients who had no varices an endoscopy did not 
have hepatic encephalopathy.
JAUNDICE AND VARICES GRADE
 
Serum bilirubin 
(µ mol/L)
VARICES GRADE
Total
No varices Small Large
<34 1 (8.3%) 6 (17.6%) 4 (15.4%) 11 (15.3%)
34-50 11 (91.7%) 27 (79.4%) 13 (50%) 51 (70.8%)
>50 0 1 (2.9%) 9 (34.6%) 10 (13.9%)
Pearsons  chisquare = 15.82   P=0.003   significant
61 out of 72 patients (85%) had jaundice. 51 patients had serum 
bilirubin in the range of 34-50 µmol/L. The range of serum bilirubin observed 
in the study was 26-58 µmol/L. Statistical analysis showed a significant `p' 
value.
MEAN SERUM BILIRUBIN IN THE STUDY GROUP
Varices 
grade
No. of 
patients
Mean 
(µ mol/L)
Std. 
Deviation
ANOVA
F-test
No varices 12 36.58 2.937
F=9.75
P=0.001
Small 34 37.21 4.545
Large 26 43.88 8.892
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The mean value of serum bilirubin for patients with no varices, small 
and  large  varices  were  36.58  µmol/L,  37.21  µmol/L  and  43.88  µmol/L, 
respectively.  An increase in the grade of varices was noted with increasing 
serum bilirubin levels.
PROTHROMBINTIME AND VARICES GRADE
Prothrombin 
time (S)
VARICES GRADE
TotalNo varices Small Large
<14 11 (91.7%) 23 (62.6%) 1 (3.8%) 35 (48.6%)
>14 1 (8.3%)  11 (32.4%) 25 (96.2%) 37 (51.4%)
25  out  of  37  patients  with  large  varices  (96.2%)  had  a  prolonged 
prothrombin  time  more  than  14  seconds,  while  91.7% of  patients  with  no 
varices had a prothrombin time less than 14 seconds.
MEAN PROTHROMBINTIME(S) IN THE STUDY GROUP
Varices 
grade N Mean(S)
Std. 
Deviation
ANOVA
F-test
No varices 12 14.08 .289
F=24.53
P=0.001
Small 34 14.47 .748
Large 26 16.50 1.881
The mean value of  prothrombin time was 16.50 seconds for  patients 
with large grade varices on endoscopy. A significant 'p' value was observed.
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SERUM ALBUMIN AND VARICES GRADE
Varices 
grade
N Mean (g/dL)
Std. 
Deviation
ANOVA
F-test
No varices 12 3.483 0.0389
F=19.5
P=0.001
Small 34 3.306 0.1324
Large 26 3.058 0.3126
61 out of 72 patients (85%) had a serum albumin level more than 3 
gm/dL, while only 15% had a serum albumin less than 3 mg/dL. The mean 
value of serum albumin for patients showed a parallel decline with increasing 
grade of varices. `P' value was significant.
SPLEEN SIZE AND VARICES GRADE
Spleen size 
(cm)
VARICES GRADE
TotalNo varices Small Large
11 cm 10 (83.3%) 21 (61.8%) 1 (3.8%) 32 (44.4%)
12 cm 2 (16.6%) 13 (38.2%) 12 (46.2%) 27 (37.5%)
13 cm 0 0 8 (30.8%) 8 (11.2%)
14 cm 0 0 5 (19.2%) 5 (7%)
Pearsons  chisquare = 15.05   P=0.001   significant
All  patients  with  no  varices  had  a  spleen  size  of  11-12  cm  on 
ultrasonography. Only one patient with large varices had a spleen size of 11cm. 
Patients with a spleen size more than 13cm were found to have only large grade 
varices.
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PLATELET COUNT AND VARICES GRADE
Platelet count 
(x103/µ l)
VARICES GRADE
TotalNo varices Small Large
<100 1 (8.3%) 8 (23.5%) 21 (80.8%) 30 (41.7%)
100-150 3 (25%) 13 (38%) 4 (15.4%) 20 (27.8%)
>150 8 (66.7%) 13 (38.2%) 1 (3.8%) 22 (30.16%)
Pearsons  chisquare = 30.1   P=0.001   significant
The minimum and maximum platelet count in 72 patients were 68x103/µ 
and  296x103/µL respectively. Platelet count of <100 x 103/µL was observed in 
30 out of 72 patients (41.7%). Among these a significant number of patients 21 
(80.8%) had large varices. Only 1 patient with no varices had a platelet count 
of  <100x103/µL.  The  above  observations  suggested  a  strong  association 
between a low platelet count and large varices, and a significant `P' value.
MEAN PLATELET COUNT IN THE STUDY GROUP (X103µ /L)
Varices 
grade
No. of 
patients
Mean 
(X103/µ L) Std. Deviation
ANOVA
F-test
No varices 12 193.33 64.714
F=18.07
P=0.001
Small 34 154.38 65.236
Large 26 89.27 27.473
The mean platelet count of patients with no varices was 193x103µL and 
small varices 154x103µL, respectively. A mean platelet count of 89.27x103µL 
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was observed in patient with large varices. This was statistically significant, as 
observed by the ANOVA F-test.
PORTAL VEIN DIAMETER AND VARICES GRADE
Portal vein 
size (cms)
VARICES GRADE
TotalNo varices Small Large
1.1 6 (50%) 12 (35%) 1 (3.8%) 19 (26.4%)
1.2 3 (25%) 11 (32%) 6 (23%) 20 (28%)
1.3 1 (8.3%) 10 (29.4%) 10 (38.5%) 21 (29.2%)
1.4-1.6 2 (16.7%) 1 (2.9%) 9 (35%) 12 (16.7%)
The  portal  vein  diameter  an  ultrasonogram  abdomen  in  72  patients 
ranged from 1.1-1.6cm. In patients with portal vein diameter <1.2cm 75% had 
no varices,  69% had small varices and only 26.8% had large varices.  Large 
varices were seen in 73.5% of patients with portal vein diameter >1.3cm.
MEAN PORTAL VEIN DIAMETER IN THE STUDY GROUP (cm)
Varices 
grade
No. of 
Patients 
Mean 
(cm)
Std. 
Deviation
ANOVA
F-test
No varices 12 1.192 .1165
F=11.67
P=0.001
Small 34 1.200 .0888
Large 26 1.319 .1132
Total 72 1.242 .1172
The mean portal vein diameter in patients with no varices on endoscopy 
was 1.192 cm compared to 1.2cm in patients with small varices and 1.319 cm 
in patients with large varices respectively. The ANOVA F-test showed 
statistical significance.
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SENSITIVITY AND SPECIFICITY OF PORTAL VEIN 
DIAMETER AND PLATELET COUNT
Portal Vein Diameter
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On univariate  analysis,  significant  correlation was noted between the 
presence of varices and child's grade, ascites, hepatic encephalopathy, palpable 
spleen, jaundice, serum albumin, prothrombin time, SAAG ratio, platelet count 
and portal  vein diameter.  Multivariate  analysis  of  variables  with significant 
correlation was then carried out using stepwise logistic regression analysis.
Parameter Significance Odds ratio
Childs grade C 0.046 5.717
Platelet count <90x103µL 0.512 2.259
Portal vein diameter >1.15cm 0.532 0.559
Childs  grade  C,  platelet  count  <90x103µL  and  portal  vein  diameter 
>1.15cm showed strong predictive values for the presence of large varices.
The sensitivity and specificity of each of the above parameters was then 
determined using the ROC curve.
Parameter Sensitivity Specificity Area under 
curve
Platelet count <90x103µL 91% 42% 0.79
Portal vein diameter >1.15cm 78% 50% 0.65
Child's grade C 100% 33% 0.66
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The sensitivity of child's grade C was 100% for predicting large varices 
while it had a poor specificity of only 33%. Platelet count <90x103/µL had a 
sensitivity  and specificity  of  91% and 42% respectively  in  predicting large 
varices. Portal vein diameter >1.15 cm had a reasonable sensitivity of 78% and 
a specificity  of 50% for the prediction of large varices.  The area under the 
curve was maximum for platelet count <90x103/µL.
Based on the above observations, a platelet count of <90x103/µL, portal 
vein  diameter  >1.15cm and  childs  grade  C  were  found  to  have  significant 
predictive value for the presence of high grade varices.
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DISCUSSION
Non  invasive  prediction  of  oesophageal  varices  in  patients  suffering 
from cirrhosis, with no history of upper GI bleed is essential as the number of 
patients  undergoing  screening  for  the  presence  of  oesophageal  varices  are 
likely to increase in the near future, as a result of the growing pool of patients 
with chronic liver disease.
Multiple  studies  have been performed to  evaluate  clinical,  laboratory 
and imaging factors that were strongly associated with the presence of varices.
PLATELET COUNT IN VARIOUS STUDIES PREDICTING 
OESOPHAGEAL VARICES
Name of study Year of study Platelet count
Present study 2004-2006 <90x103/µL
Chalasani et al.42 1999 <88x103/µL
Schepis et al.43 2001 <100x103/µL
Zaman et al.44 1999 <88x103/µL
Sarwar et al.45 2003-2004 <88x103/µL
Gill et al.46 2004 <140x103/µL
Many studies have been conducted which have shown a low platelet 
count to be an independent predictor of the presence of large varices. Most of 
the studies have clearly revealed that a platelet count less than 88x103/µL is 
associated with large varices an endoscopy. In the present study platelet count 
of  <90x103/µL  showed  significant  association  with  the  presence  of  large 
varices.
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PORTAL VEIN DIAMETER IN VARIOUS STUDIES PREDICTING 
OESOPHAGEAL VARICES 
Name of study Year of study Portal vein diameter
Present study 2004-2006 >1.15 cm
Schepis et al.43 2001 >1.3 cm
Sarwar et al.45 2003-2004 >1.1 cm
A very few studies have detailed the portal vein size to be a predictor of 
large varices. The portal vein size predicting large varices in our study was 
very similar to that observed in the study by Sarwar et al.
Many of the studies conducted to predict the presence of oesophageal 
varices non invasively also found significant association with parameters other 
than portal vein diameter and platelet count.
 Chalasani  et  al.42 found  that  in  addition  to  a  platelet  count 
<88x103/µL,  splenomegaly  was  independently  associated  with  the 
presence of large varices.
The present study failed to show any significant association between 
splenomegaly and presence of large varices.
 Schepis  et  al.43 found  a  prothrombin  activity  <70%,  portal  vein 
diameter  >1.3  cm  and  platelet  count  <100x103/µL  significantly 
associated with oesophageal varices.
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The present study showed lesser values for both platelet count and portal 
vein  diameter  in  detecting  oesophageal  varices  and  no  strong  association 
between prothrombin time and presence of large varices.
 Zaman et al.44 found that a platelet count <88x103/µL was strongly 
associated  with  the  presence  of  oesophageal  varices.  The  present 
study showed very similar results with only a minor difference of 
2x103/µL in platelet count.
 Sarwar et al.45 found that patients with serum albumin <2.95g/dL, 
platelet  count  <88x103/µL and  portal  vein  diameter  >11  mm are 
more likely to have high grade oesophageal varices an endoscopy. 
In  our  present  study  results  were  nearly  similar  but  serum  albumin 
showed  no  significant  association  with  the  presence  of  large  oesophageal 
varices.
 Gill  et  al.46 identified  oesophageal  varices  in  70%  cases  when 
surveillance endoscopy was performed only in cirrhosis patients with 
platelet  count  <1,40,000/  µL,  INR>1.5 and portal  vein  diameter> 
13mm.
Our study results are in variance with the above study.
All the studies have shown an association between a low platelet count 
and high grade varices on endoscopy.
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In  the  present  study,  three  factors  were  identified  which  had  an 
independent association with presence of varices. Childs grade C, platelet count 
<90x103/µL and portal vein diameter >1.15cm were significant predictors after 
multivariate analysis for the presence and grade of oesophageal varices.
Portal vein diameter >1.15cm had significant correlation with high grade 
varices with sensitivity and specificity of 78% and 50% respectively. Width of 
portal vein on ultrasonographic examination is an indirect indicator of portal 
pressure which is responsible for development of varices.
Platelet count <90x103/µL had significant correlation with high grade 
varices with sensitivity and specificity of 91% and 42% respectively.
Patients under Childs grade C had a sensitivity and specificity of 100% 
and 33% respectively in identifying high grade varices.
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CONCLUSION
 Platelet  count  <90x103/µL,  portal  vein  diameter  >1.15  cm  on 
ultrasonography  and  childs  grade  C  are  independently  associated 
with the presence of high grade varices.
 Patients with established cirrhosis and no past history of upper GI 
bleed should have surveillance endoscopy if any of these parameters 
is identified.
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SUMMARY
Seventy two patients  with cirrhosis of the liver without any previous 
history of upper GI bleed were studied to identify non endoscopic parameters 
which  could  predict   the  presence  of  oesophageal  varices.  Platelet  count 
<90x103/µL, portal vein diameter >1.15cm and childs grade C were found to be 
independently associated with presence of large varices on endoscopy. Patients 
with any of these parameters are candidates for surveillance endoscopy.
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PROFORMA
NON ENDOSCOPIC PREDICTORS OF OESOPHAGEAL 
VARICES IN PATIENTS WITH CIRRHOSIS OF THE LIVER
1. Name
2. Age/Sex:
3. Address:
4. IP No. Date of admission:
5. Occupation:
6. Income:
7. Habits:
Alcohol
Smoking
IV drug abuse/Exposure to CSW
Month/Year/Hospital of diagnosis of liver disease
Duration of disease
Current drugs taken
8. Clinical details (symptom-duration)
GI Bleed
Haematemesis
Malena
Rectal bleeding
Ascites
Jaundice
Oliguria
Symptoms of hepatic encephalopathy
9. Comorbid illness (DM/HT/COPD/CVA/Seizures/Others)
10. Clinical examination:
Pallor
65
Icterus
Clubbing
Cyanosis
Pedal Edema
KF ring
Vitals
Pulse rate
Blood Pressure
Respiratory rate
JVP
Signs of bleeding skin/nose/gums
CNS examination
CVS
Respiratory system
Abdomen
Free fluid
Splenomegaly
11. Investigations:
Complete Hemogram
Platelet count
BT/CT
Blood sugar
RFT
Urea
Creatinine
Electrolytes
LFT
Total/Direct Bilirubin
ALT
AST
SAP
Total protein
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S.Albumin
Ascitic Fluid Analysis
Sugar/Protein
Cell Count
Cytology
Gramstain/AFB
Culture
SAAG ratio
Prothrombin time/INR
Chest X-ray
ECG
UGI Endoscopy
Varices grade
EST
USG abdomen
Portal vein size
Spleen size
Ascites
Viral markers (HBsAg, Anti HCV)
Child's Grading
A/B/C
12. Treatment
Drugs
Sclerotherapy
13. Outcome
Discharge
Death
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